PLATFORM Study of Precision Medicine for Rare Tumors
Status:
Not yet recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
A Phase II, open label, non-randomized, multiple-arm, single-center clinical trial in
patients with advanced rare solid tumors who failed to standard treatment.
Phase:
Phase 2
Details
Lead Sponsor:
Cancer Institute and Hospital, Chinese Academy of Medical Sciences